MK-677 vs Ipamorelin

Neither, technically. MK-677 (ibutamoren) is a small-molecule non-peptide ghrelin receptor agonist. It is not a peptide because it is not made of amino acids - it is a synthetic chemical that happens to hit the same receptor peptides like ipamorelin activate. It is not a SARM (selective androgen receptor modulator) either, despite being sold alongside SARMs in the research chemical market. The correct category is growth hormone secretagogue, same receptor family as ghrelin mimetics.

Yes, and not the kind you want. MK-677 causes significant water retention (often 5-10 pounds in the first weeks) and notable appetite increases via ghrelin receptor activation. Some users gain actual fat mass along with any muscle gains because hunger is hard to control. It can also cause insulin resistance with prolonged use. Ipamorelin does not have these issues - its pulsatile action avoids the chronic appetite stimulation that makes MK-677 hard to use for body composition goals.

Merck developed ibutamoren (then MK-0677) for elderly frailty and hip fracture recovery through multiple Phase 2 and Phase 3 trials in the late 1990s and 2000s. The program was ultimately abandoned due to concerns about congestive heart failure risk, insulin resistance, and edema in elderly populations, along with questionable clinical benefit. It never received FDA approval. It is now sold as a research chemical with no legitimate prescription pathway in the US.

MK-677, by a significant margin. The continuous 24-hour ghrelin receptor activation causes water retention, appetite spikes, insulin resistance, occasional fatigue, and has been flagged for congestive heart failure risk in elderly cohorts. Ipamorelin's pulsatile action sidesteps most of these issues - it is the cleanest GHRP available with no cortisol or prolactin elevation at therapeutic doses. If side effect tolerability is the priority, ipamorelin wins clearly. If convenience (oral vs injection) matters more, MK-677 is the only option.

MK-677 works via Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1. Ipamorelin works via Selective growth hormone secretagogue that binds to ghrelin receptors to stimulate GH. They differ in FDA approval status, efficacy data, and cost.

MK-677 typically costs $50 - $100/mo, while Ipamorelin costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

MK-677 is not FDA-approved (Phase 2). Ipamorelin is not FDA-approved (Category 2 (pending reclassification)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of MK-677 include Increased appetite, Water retention, Fatigue. Common side effects of Ipamorelin include Injection site reactions, Increased hunger, Headache. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.